Proteomic analysis for developing new biomarkers of hepatocellular carcinoma

World Journal of Hepatology

Volumn 2, Issue 3, 2010, Pages 127-135

  Pleguezuelo, Maria ^a   Lopez Sanchez, Laura M ^a   Rodriguez Aritza, Antonio ^a   Montero, Jose L ^a   Briceno, Javier ^a   Ciria, Ruben ^a   Muntane, Jordi ^a   de la Mata, Manuel ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

2D polyacrylamide gel electrophoresis; Apolipoproteins; Liver cancer; Mass spectrometry; Serum biomarkers

Indexed keywords

EID: 84865234573     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v2.i3.127     Document Type: Article

References (26)

1. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27-S34
2. Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, Wagner PD. The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. Cancer Biomark 2008; 4: 19-33
3. Santamaría E, Muñoz J, Fernández-Irigoyen J, Prìeto J, Corrales FJ. Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics. Liver Int 2007; 27: 163-173
4. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346
5. Yoon SK, Lim NK, Ha SA, Park YG, Choi JY, Chung KW, Sun HS, Choi MJ, Chung J, Wands JR, Kim JW. The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res 2004; 64: 5434-5441
6. Chignard N, Beretta L. Proteomics for hepatocellular carcinoma marker discovery. Gastroenterology 2004; 127: S120 S125
7. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430
8. Gupta S, Bent S, Kohlwes J. Test characteristics of alphafetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003; 139: 46-50
9. Leerapun A, Suravarapu SV, Bida JP, Clark RJ, Sanders EL, Mettler TA, Stadheim LM, Aderca I, Moser CD, Nagorney DM, LaRusso NF, de Groen PC, Menon KV, Lazaridis KN, Gores GJ, Charlton MR, Roberts RO, Therneau TM, Katzmann JA, Roberts LR. The utility of Lens culinaris agglutinin- reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol 2007; 5: 394-402; quiz 267
10. Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol 2007; 102: 2196-2205
11. Pleguezuelo M, Germani G, Marelli L, Xiruochakis E, Misseri M, Pinelopi M, Arvaniti V, Burroughs AK. Evidencebased diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008; 2: 761-784
12. Elrick MM, Walgren JL, Mitchell MD, Thompson DC. Proteomics: recent applications and new technologies. Basic Clin Pharmacol Toxicol 2006; 98: 432-441
13. Ishak KG. Chronic hepatitis: morphology and nomenclature. Mod Pathol 1994; 7: 690-713
14. Jiang JT, Wu CP, Xu N, Zhang XG. Mechanisms and significance of lipoprotein (a) in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2009; 8: 25-28
15. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997; 157: 792-796
16. Tietge UJ, Boker KH, Bahr MJ, Weinberg S, Pichlmayr R, Schmidt HH, Manns MP. Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. Hepatogastroenterology 1998; 45: 2255-2260
17. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-5890
18. Fernández-Irigoyen J, Santamaría E, Sesma L, Muñoz J, Riezu JI, Caballería J, Lu SC, Prieto J, Mato JM, Avila MA, Corrales FJ. Oxidation of specific methionine and tryptophan residues of apolipoprotein A-I in hepatocarcinogenesis. Proteomics 2005; 5: 4964-4972
19. Motta M, Giugno I, Ruello P, Pistone G, Di Fazio I, Malaguarnera M. Lipoprotein (a) behaviour in patients with hepatocellular carcinoma. Minerva Med 2001; 92: 301-305
20. Alsabti EA. Serum lipids in hepatoma. Oncology 1979; 36: 11-14
21. Ooi K, Shiraki K, Sakurai Y, Morishita Y, Nobori T. Clinical significance of abnormal lipoprotein patterns in liver diseases. Int J Mol Med 2005; 15: 655-660
22. Geiss HC, Ritter MM, Richter WO, Schwandt P, Zachoval R. Low lipoprotein (a) levels during acute viral hepatitis. Hepatology 1996; 24: 1334-1337
23. Basili S, Andreozzi P, Vieri M, Maurelli M, Cara D, Cordova C, Alessandri C. Lipoprotein (a) serum levels in patients with hepatocarcinoma. Clin Chim Acta 1997; 262: 53-60
24. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-1232
25. Kang SK, Chung TW, Lee JY, Lee YC, Morton RE, Kim CH. The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylgl ucosaminyltransferase III. J Biol Chem 2004; 279: 28106-28112
26. Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 2006; 5: 4